Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914067 · ClinicalTrials.gov registry record · NA
Cognitive Biomarkers in Pediatric Brain Tumor Patients
A NA study of Childhood Brain Tumor, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT02914067 is a NA study of Childhood Brain Tumor that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02914067, a NA study of Childhood Brain Tumor, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will focus on three cohorts of brain tumor patients aged, 4-18 years, to answer two critical questions: 1) Can the investigators acquire high quality data relevant to cognitive function during the peri-diagnostic period and, 2) can the investigators develop predictive models for cognitive outcomes using serial examination of functional imaging and cognitive function. Any patient with a newly diagnosed brain tumor aged 4-18 will be eligible for enrollment in cohort 1. Only patients with previously diagnosed tumors of the posterior fossa will be eligible for cohort 2. For cohort 3, eligible patients will include patients with a clinical diagnosis of posterior fossa syndrome with physical impairments that prohibit completion of the NIH Toolbox Cognitive Battery. The investigators have decided to expand the eligible tumor types to better capture the most significant deficit variability that can be caused by tumors outside the posterior fossa. Thus, this focus will provide a platform to analyze the impact that different tumor types and different standard treatments have on cognitive dysfunction. The rationale for inclusion of subjects on cohort 3 is that posterior fossa syndrome is one of the most cognitively devastating diagnoses following a posterior fossa surgery. The causes of posterior fossa syndrome and unknown and there are currently no interventions to improve symptoms. RsfcMRI would offer a novel and non-invasive assessment of posterior fossa syndrome patients by assessing connectivity within and outside of the cerebellum. Expanding the tumor eligibility will allow us to further explore the effect tumor location will have on cognitive testing and rsfcMRI. Here, repeated evaluations on and off therapy will provide the necessary data points to establish trajectories of cognitive development and recovery in this population.
Conditions Studied
Interventions
- OTHER Neurocognitive testing
- DEVICE rsfcMRI
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2016-10-26 |
| Est. Completion | 2029-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02914067
The ClinicalTrials.gov registry entry for NCT02914067 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Childhood Brain Tumor appearing as the primary indexed condition, and to 2 interventions - of which Neurocognitive testing is the first listed.
NCT02914067 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT02914067 about?
NCT02914067 is a clinical study titled "Cognitive Biomarkers in Pediatric Brain Tumor Patients". The investigators will focus on three cohorts of brain tumor patients aged, 4-18 years, to answer two critical questions: 1) Can the investigators acquire high quality data relevant to cognitive function during the peri-diagnostic period and, 2) can the investigators develop predictive models for co...
What is the current status of trial NCT02914067?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2016-10-26. Estimated completion is 2029-01-31.
What conditions does trial NCT02914067 study?
This clinical trial studies the following conditions: Childhood Brain Tumor.
What interventions are being tested in trial NCT02914067?
The interventions under investigation include: Neurocognitive testing (OTHER), rsfcMRI (DEVICE).
Who is sponsoring clinical trial NCT02914067?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02914067 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.